Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
|
|
- John Simon
- 6 years ago
- Views:
Transcription
1 Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H.
2 Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for patients taking them Describe the risks of prolonged immunosuppressive therapy including the most common infections and malignancies
3 Outline Evolution of immunosuppression Immunosuppressive drugs: how they work and their potential toxicities Commonly used combination of immunosuppressive drugs If Infections Malignancies
4
5 Kidney Transplantation: Earlier Experiences
6 Overcoming the Barriers
7
8 Allorecognition After Kidney Transplantation Halloran P. NEJM.(351)2715, 2004
9 Targets of Immunosuppressive Therapy Halloran P. NEJM ( 351 ), 2715, 2004
10 Corticosteroids Inhibit APC/monocyte interaction Inhibit IL-2, IL-1 1, IL-3 3, IL-15 15, IFN, TNF transcription Highly effective Cheap Toxicities: HTN, DM, obesity, AVN osteoporosis, peptic p ulcers, acne, psychosis
11 Calcineurin Inhibitors The cornerstone of immunosuppression Inhibit the production of many cytokines Cyclosporine: introduced in 1983, Sandimmune and later Neoral, now has many generic competitors; cyclosporine modified, Gengraf, Neon Tacrolimus: known as FK506, Prograf and several generics are being introduced d
12 Calcineurin Inhibitors Cyclosporine, Tacrolimus Prevent expression of IL-2 Block T cell activation Potential short and long term nephrotoxicity
13 Beware of Modulators of CYP450-3A4 Inhibitors(increase levels) Diltiazem Verapamil Ketoconazole Itraconzole Voriconazole Fluconazole Erythromycin Clarithromycin Zithromax Grapefruit Juice Inducers(decrease levels) Rifampin Izoniazid id Dilantin Tegretol Phenobarbitol St. John s Wort
14 Calcineurin Inhibitors Side Effects Profiles Cyclosporine Tacrolimus Hyperkalemia Hyperlipidemia Tremor + ++ Hyperglycemia + ++ Hirsutism ++ Gingival Hyperplasia ++ Nephrotoxicity ++ ++
15 Cumulative Incidence of Chronic Renal Failure among 69,321 Persons Who Received Nonrenal Organ Transplants in the United States between January 1, 1990, and December 31, 2000 Ojo, A. et al. N Engl J Med 2003;349:
16 Anti-Proliferative Agents Azathioprine : Imuran Mycophenolate Mofetil : Cellcept/Myfortic Sirolimus/Evrolimus :Rapamune/Zortress Leflunomide: Arava
17 Azathioprine Blocks purine metabolism Dose: 1-2 mg/kg PO qd Side effects: Myelosuppression Skin cancer Hepatitis Never use with Allopurinol
18 Mycophenolate Mofetil (Cellcept/Myfortic) Inhibitor of DNA synthesis by blocking inosine monophosphate p dehydrogenase Selective effect on lymphocytes May block adhesion molecules necessary for lymphocyte homing to allograft
19 Mycophenolate Mofetil (Cellcept/Myfortic) Available in both IV and PO forms Usual dose is 1g BID/720 mg BID Side effects higher at higher doses Diarrhea Leukopenia Thrombocytopenia Increased CMV severity
20 Sirolimus /Evrolimus Blocks T and B cell activation Side effects: Increases nephrotxicity of CyA, Tac Hyperlipidemia Leukopenia Thrombocytopenia Delayed wound healing Alters cyclosporine metabolism
21
22 Long Term Post-Transplant sp a Complications o Infectious complications Malignancy CKD-T
23 Infectious Complications After Transplantation
24 Tissue Diagnosis is Most Important
25
26 Principles guiding Management of Post transplant Infections Prevention of life threatening infections is the goal Preclinical diagnosis and preemptive therapy is achievable in some infections Early definitive diagnosis( tissue diagnosis) is extremely important and avoiding drug interactions
27 Malignancies after Solid Organ Transplantation Skin cancers are greatly increased PTLD/Post transplant lymphoproliferative disorder is increased but remains limited Risk of other solid organ malignancies are increased but not a major cause of morbidity or mortality
28 Overall Incidence of Malignancy After Transplantation % Time After Transplantation (Years) Penn I. Transplant Sci. 1994;4:23-32.
29 Most Commonly Reported Posttransplant Malignancies* Skin and lip cancer Squamous cell carcinoma (SCC) Basal cell carcinoma (BCC) Merkel cell carcinoma Melanoma PTLD Liver and kidney cancers *Confirmed by different registries, including the Israel Penn International Transplant Tumor Registry (formerly Cincinnati Transplant Tumor Registry), the Australia-New Zealand Dialysis and Transplantation Registry and the United Network for Organ Sharing.
30 Skin Cancer in Transplant Recipients Differs From the General Population SCC is more common than BCC Merkel cell carcinoma, a neuroendocrine cancer of the skin, is more frequent in the transplant population Lesions develop at a younger age (30 versus 60 years) and occur in multiple sites Tumors are more aggressive and are more likely to recur after resection
31 Skin Cancers in Transplant and the General Population Transplant General Population SCC/BCC 1.8:1 1:5 Melanoma 5.2% 2.7% Patient age Lymph node involved 5.8% Rare Mortality 4.9% 1.5%
32 Viruses Associated With Certain Types of Cancer EBV with non- Hodgkin s lymphoma and PTLD Ubiquitous virus in >90% of general population 90% overall incidence of EBV+ tumors Higher incidence of PTLD in pediatric population is potentially related to the higher incidence of EBVnaive recipients HPV with cervical Etiologic i factor for cervical cancer in the general cancer population Higher incidence of HPV co-infection in transplant recipients than nontransplant patients with cervical cancer HHV-8 with Kaposi s Sporadic or epidemic occurrence sarcoma Presents as either cutaneous or visceral Often seen in immunocompromised patients Correlated with Mediterranean heritage
33 PTLD 2nd most common de novo malignancy following renal transplantation More than 93% of lymphoid cancers are non-hodgkin s lymphoma Compare with 65% in nontransplant patients Incidence peaks in the 1st year after surgery Risk is highest during the 1st year, when level of immunosuppression is most intense Sayegh MH, et al. Up to Date Online [serial online]. June 25, 2001; version 10.1.
34 Management of Solid Tumors Standard Modalities Treatment Regimen Alterations Standard surgery Radiotherapy Chemotherapy Discontinue antimetabolites (azathioprine, mycophenolate mofetil) Decrease calcineurin inhibitors Consider altering maintenance therapy
35 Immunosuppressive Treatment: The Standard Protocol in 2012 Induction: anti CD-25 or Thymoglobulin Maintenance immunosuppression: Choice of Calcineurin inhibitor: Tacrolimus vs. Cyclosporin Anti-proliferative: Mycophenolate or Sirolimus Steroid withdrawal vs. low dose prednisone
36 The Goal of Immunosuppression in 2012 Optimize combined regimen to: - Minimize rejection - Minimize toxicity Can optimize therapy for high risk patients Tailor immunosuppressive drug regimen to fit the individual patient s risks and side-effects profile Avoid and monitor for potential drug interactions
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationMedications in the Solid Organ Transplant Recipient
Medications in the Solid Organ Transplant Recipient Monica Morgan, PharmD Transplant Pharmacist UT Southwestern Medical Center Solid Organ Transplant Program Objectives To describe the typical medications
More informationOBJECTIVES. Phases of Transplantation and Immunosuppression
Transplant and Immunosuppression: Texas Transplant Center April 29, 2017 Regina L. Ramirez, Pharm.D., BCPS PGY1 Pharmacy Residency Program Director Clinical Practice Specialist Solid Organ Transplant and
More informationObjectives. The Immune Response. Mechanisms of T-Cell Activation. Balancing Act of Transplant 4/22/2015. Maintenance Immunosuppression
Objectives Medication Needs of Transplant Recipients: Protecting the Gift of Life Adam Diamond, PharmD, BCPS Solid Organ Transplant Clinical Pharmacy Specialist Lahey Hospital and Medical Center Christin
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationChronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP
Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital
More informationFellows Conference 01/21/2016
Fellows Conference 01/21/2016 Outline Basics of transplantation Benefits of transplantation Immunosuppressive medications Anatomy of Renal Transplantation Recipient Selection General medical condition.
More informationLiver Transplant Immunosuppression
Liver Transplant Immunosuppression Michael Daily, MD, MS, FACS Surgical Director, Kidney and Pancreas Transplantation University of Kentucky Medical Center Disclosures No financial disclosures I will be
More informationIMMUNOSUPPRESSIVE THERAPY Overview. Desensitization
IMMUNOSUPPRESSIVE THERAPY Overview Two types of immune responses to allografts: Cellular response: foreign antigen recognition activate antigen-specific lymphocytes (T-cells) o Key mediator: T-cells o
More informationPsychiatric Transplant Evaluation
Psychiatric Transplant Evaluation Psychiatry in Medical Settings February 2017 Shehzad K. Niazi, MD, FRCPC 2015 MFMER slide-1 Objectives Recognize the impact of psych. comorbidities on outcomes Understand
More informationInnovation In Transplantation:
Innovation In Transplantation: Improving outcomes Thomas C. Pearson Department of Surgery Emory Transplant Center CHOA Symposium October 22, 2016 Disclosures Belatacept preclinical and clinical trial were
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationBetter than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
More informationTransplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005
Transplant Overview Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 CTI Clinical Trial and Consulting Services Drug Development Company focused in key
More information9/30/ DISCLOSURES. + First: Why immunosuppress? Transplant Immunosuppression and Prophylaxis
Transplant Immunosuppression and Prophylaxis Sarah Fitz, APN, MSN, ACNP-BC Loyola University Medical Center DISCLOSURES I am not being paid by any entity to endorse a specific product. Any mention of brand
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More informationIt s just not that into you:
CSHP Clinical Symposium - It s just not that into you: The no-excuses truth to understanding rejection and transplant pharmacology Erica D. Greanya, PharmD Clinical Pharmacy Specialist Solid Organ Transplantation
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationWhat Every Non-hepatologist Should Know About Caring For Transplanted Patients. Gia Tyson, MD, MPH Ochsner Health System March 31, 2017
What Every Non-hepatologist Should Know About Caring For Transplanted Patients Gia Tyson, MD, MPH Ochsner Health System March 31, 2017 Agenda Liver transplant statistics Post-transplant patient information
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationLiver Transplant: What s Different? Brian Lin, MD, FACEP Emergency Medicine, Kaiser Permanente, San Francisco UCSF Clinical Assistant Professor
Liver Transplant: What s Different? Brian Lin, MD, FACEP Emergency Medicine, Kaiser Permanente, San Francisco UCSF Clinical Assistant Professor No Disclosures. Background 45 years 1998-2008: 90,830 transplants
More informationFor Immediate Release Contacts: Jenny Keeney Astellas US LLC (847)
For Immediate Release Contacts: Jenny Keeney Astellas US LLC (847) 317-5405 Lauren McDonnell GolinHarris (312) 729-4233 ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF (TACROLIMUS) IN CONJUNCTION WITH
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationRenal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program.
Renal Transplant Tony Chacon Program Head BCIT Nephrology Nursing Program Email: tony_chacon@bcit.ca Summary of CNA Renal Transplant Competencies Potential contraindications to renal transplant. Assessment/selection
More informationManipulation of the Immune Response - Immunomodulation -
Manipulation of the Immune Response - Immunomodulation - Janeway s Immunobiology, 9 th ed., 2017. Ivana Novak Nakir Immune system Immune system make components, cells and organs that act together to defend
More information1. Discuss the basic pathophysiology of end-stage liver and kidney failure.
TRANSPLANT SURGERY ROTATION (PGY1, 2) A. Medical Knowledge Goal: The resident will achieve a detailed knowledge of the evaluation and treatment of a variety of disease processes. The resident will be exposed
More informationKidney Transplantation: What Pharmacists & Technicians Need to Know
Kidney Transplantation: What Pharmacists & Technicians Need to Know Amanda J. Condon, PharmD, BCPS Solid Organ Transplant Pharmacist University of New Mexico Hospitals Objectives PHARMACIST Describe mechanisms
More informationSolid Organ Transplantation
LOGO Solid Organ Transplantation Dr. Mohammad Taraz Clinical Pharmacist June 2011 2 Introduction Solid organ transplantation is a well accepted therapeutic option for patients with end-stage kidney, liver,
More informationClinical decisions regarding immunosuppressive
PHARMACOLOGIC THERAPIES AND RATIONALES * Stuart D. Russell, MD ABSTRACT This article reviews evidence related to the use of induction therapy and longer-term combination immunosuppressive drug regimens
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationLong term liver transplant management
Long term liver transplant management Dr Bill Griffiths Cambridge Liver Unit Royal College of Physicians 5.7.17 Success of Liver Transplantation Current survival, 1 st elective transplant: 1 yr survival
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More informationKIDNEY TRANSPLANTATION FOR THE INTERNIST. Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.
KIDNEY TRANSPLANTATION FOR THE INTERNIST Marc Richards MD South Florida Kidney Disease and Hypertension Specialists BRRH Grand Rounds 5.8.2018 Goal of Lecture: OUTLINE CKD -> ESRD Workup for Transplant
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationImmunosuppressant medicines have allowed patients
48 Clinical Pharmacist February 2010 Vol 2 Patients who tolerate a transplanted organ without the need for pharmacological intervention are few and far between. Several immunosuppressants can be used to
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 NULOJIX 250 mg, powder for concentrate for solution for infusion B/1 (CIP code: 580 415-7) B/2 (CIP
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationIntruduction PSI MODE OF ACTION AND PHARMACOKINETICS
Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University
More informationLiterature Review Transplantation
Literature Review 2010- Transplantation Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs University of
More informationDivya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology
Divya Jain Arwindekar, DO Transplant Nephrologist Advocate Christ Medical Center & Associates in Nephrology Not a cure to kidney disease, but it is a very effective treatment Patients still have chronic
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More information2/28/2017. Adult Heart Transplants Donor and Recipient Characteristics UNOS, Retransplant VCM. Other /2015 (N = 24,474)
1 46% 2% 3% 4% 0% 2% 2% CHD HCM ICM NICM RCM 49% 3% 3% 3% 1% 3% 3% Retransplant VCM 42% Other 35% 1/1982 6/2015 1/2009 6/2015 2016 JHLT. 2016 Oct; 35(10): 1149-1205 UNOS, 2017 Adult Heart Transplants Donor
More informationInfection in the Solid Organ Transplant Patient adapted from Osler chapter by David Lim, M.D., Ph.D. and Aruna Subramanian, M.D.
Infection in the Solid Organ Transplant Patient adapted from Osler chapter by David Lim, M.D., Ph.D. and Aruna Subramanian, M.D. 50-75% of pts get infected w/in 1 st year INTERCONNECTED GOALS 1. prevent
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationPleiotropic effects of mtor inhibitors : cardiovascular and cancer. Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble
Pleiotropic effects of mtor inhibitors : cardiovascular and cancer Dr Paolo Malvezzi Clinique de Néphrologie CHU Grenoble Tehran August 2016 Why this topic? Since last year very little news in the immunosuppressive
More informationThe 1990s have seen major steps in the dissection of basic mechanisms
Immunosuppressive Therapy and Protocols Angelo M. de Mattos The 1990s have seen major steps in the dissection of basic mechanisms of allorecognition, and renal graft survival has achieved unprecedented
More informationWARNING: MALIGNANCIES AND SERIOUS INFECTIONS,
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZORTRESS safely and effectively. See full prescribing information for ZORTRESS. ZORTRESS (everolimus)
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationCancer of the head and neck region in solid organ transplant recipients
ORIGINAL ARTICLE Cancer of the head and neck region in solid organ transplant recipients Naomi Rabinovics, MD, 1 * Aviram Mizrachi, MD, 1 Tuvia Hadar, MD, 1 Dean Ad-El, MD, 2 Raphael Feinmesser, MD, 1
More informationCancer in kidney transplant recipients: epidemiology and prevention
BTS 2018, Brighton Cancer in kidney transplant recipients: epidemiology and prevention Adnan Sharif Queen Elizabeth Hospital Birmingham Outline 1. The burden of cancer after kidney transplantation 2. Epidemiology
More informationObserved Whole Blood Trough Concentrations. Recommended Initial Oral Dosage (two divided doses every 12 hours)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROGRAF safely and effectively. See full prescribing information for PROGRAF. PROGRAF (tacrolimus)
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationPanGraf Tacrolimus Capsules 0.5 / 1.0 / 5.0
For the use of a Nephrologist / Transplant Surgeon or a Hospital or a Laboratory only PanGraf Tacrolimus Capsules 0.5 / 1.0 / 5.0 DESCRIPTION Tacrolimus is a macrolide lactone with potent immunosuppressive
More information15 Immunodeficiencies
15 Immunodeficiencies A. Acquired causes of immunodeficiencies 1. Environmental (UV irradiation) 2. Drug induced (immunosuppressants) 3. non-hiv Viral (measles virus) Dr. Andrea Hubbard School of Pharmacy
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationTransplantation simplified. Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK
Transplantation simplified Dr Jasna Macanovic Consultant Nephrologist Wessex Renal and Transplant Services Portsmouth, UK HISTORY The first successful kidney transplant was performed in 1954 between identical
More informationVictims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham
Victims of success: Do we still need clinical trials? Robert S. Gaston, MD CTI Clinical Trials and Consulting University of Alabama at Birmingham Disclosure Employee: CTI Clinical Trials and Consulting
More informationImmunosuppressive therapy for graft-versus-host disease. Mohamad Mohty Institut Paoli-Calmettes, Marseille
Immunosuppressive therapy for graft-versus-host disease Mohamad Mohty Institut Paoli-Calmettes, Marseille Survival according to GVHD grade (Joint SFGM-TC, DFCI and IBMTR data; N=607) Cahn et al., Blood
More informationDental Management of the Organ or Stem Cell Transplant Patient
Dental Management of the Organ or Stem Cell Transplant Patient KEY POINTS Before and after organ or stem cell transplantation, patients require specialized dental management. Optimal dental management
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationPlease submit supporting medical documentation, notes and test results.
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Valcyte (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationDonation Process. Brain Death. Brain Death
Donation Process Hospital notifies OPO of potential donor OPO coordinator assesses potential donor and takes over care after brain death Laboratories and ancillary tests performed Organ placement Arranging
More informationKidney Transplant. November 4 th, 2016
Kidney Transplant November 4 th, 2016 Brad West, MD, FACP Medical Director of Transplant Services, Memorial Medical Center Chairman Department of Nephrology, Springfield Clinic 1 Adjusted survival: 1993-1997
More informationCarolyn Bangert, MD Associated Dermatologists, PC
Carolyn Bangert, MD Associated Dermatologists, PC Carolyn Bangert, MD Systemic Medications for the Dermatology Toolbox: Cyclosporine I have no relevant conflicts of interest with any companies. I will
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationImmunizing the Immunocompromised. Leilani T. Sanchez, MD, DPPS, DPIDSP Crowne Plaza Galleria Manila, 21 February 2013
Immunizing the Immunocompromised Leilani T. Sanchez, MD, DPPS, DPIDSP Crowne Plaza Galleria Manila, 21 February 2013 WHO World Health Statistics 2012 2 Immunizing the Immunocompromised Leilani T. Sanchez
More information2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants
2017 CST-Astellas Canadian Transplant Fellows Symposium Management of Renal Dysfunction in Extra Renal Transplants Jeffrey Schiff, MD Dr. Jeffrey Schiff is an Assistant Professor of Medicine at the University
More informationPrescribing Framework for Ciclosporin Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Ciclosporin Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationDisclosures. CMV and EBV Infection in Pediatric Transplantation. Goals. Common Aspects CMV (Cytomegalovirus) and EBV (Epstein-Barr virus)
Disclosures I have financial relationships with the following companies: CMV and EBV Infection in Pediatric Transplantation Elekta Inc Lucence Diagnostics Spouse employed Spouse employed I will not discuss
More informationPotential Catalysts in Therapeutics
LIVER TRANSPLANTATION 20:S22 S31, 2014 SUPPLEMENT Potential Catalysts in Therapeutics Bruce A. Luxon Division of Gastroenterology-Hepatology, University of Iowa, Iowa City, IA Received July 23, 2014; accepted
More informationOverview of Kidney Transplantation
Overview of Kidney Transplantation Marie Morgievich RN, MS, APN.C Renal & Transplant Nurse Practitioner Saint Barnabas Medical Center Topics 1. History of Transplant 2. Treatment options for Chronic Kidney
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationKidney transplantation 2016: current status and potential challenges
Kidney transplantation 2016: current status and potential challenges 15/12/2016 BVN-SBN : State-of-the-Art on Kidney Transplantation Patrick Peeters Ghent University Hospital, Belgium Challenges in 2016
More informationTACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver disease
Oxford Gastroenterology Unit Shared Care Protocol & Information for GPs TACROLIMUS (PROGRAF, Modigraf Adoport, Adagraf ) Prescribing Guidelines for Adult Liver Transplant Patients and autoimmune liver
More informationShared Care Guidelines. In partnership with Acute Trust & PCTs. SIROLIMUS In renal transplant. August 2016
Shared Care Guidelines In partnership with Acute Trust & PCTs SIROLIMUS In renal transplant August 2016 Page 0 of 12 Table of Contents Introduction 2 Licensing 2 Referral 2 Initiation and maintenance of
More informationTransplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017
Transplant Immunosuppression in 2017 Hepatobiliary Liver Transplant Symposium 2017 Dr AJ Terblanche Paediatric Gastroenterology and Hepatology Unit, SBAH Paediatric Transplant Unit Wits Donald Gordon Medical
More informationPREVALENCE AND TREATMENT OF HYPERTENSION IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS
PREVALENCE AND TREATMENT OF HYPERTENSION IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS Zbigniew Heleniak, Izabella Kuźmiuk, Hanna Garnier, Jakub Wiśniewski, Dorota Adrych, Przemysław Rutkowski, Leszek Tylicki,
More informationAmerican Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc.
American Journal of Transplantation 2009; 9 (Suppl 3): S1 S157 Wiley Periodicals Inc. 2009 The Authors Journal compilation 2009 The American Society of Transplantation and the American Society of Transplant
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationImmunosuppressant Medications
Immunosuppressant Medications Brian C. Keller, MD, PhD Assistant Professor of Medicine Division of Pulmonary, Critical Care & Sleep Medicine The Ohio State University Wexner Medical Center Presentation
More informationImmunosuppressant. Indications. Goals of immunosuppressive therapies. Evolution of immunosuppressive therapies
Immunosuppressant Medications Presentation outline Evolution of immunosuppressive therapies Common indications for immunosuppression Brian C. Keller, MD, PhD Assistant Professor of Medicine Division of
More informationImmunosuppression for pediatric cardiac transplantation in the modern era
Ž. Progress in Pediatric Cardiology 11 2000 115 129 Immunosuppression for pediatric cardiac transplantation in the modern era Bill A. Pietra, Mark M. Boucek Department of Pediatrics, Uni ersity of Colorado
More informationRisk factors associated with post kidney transplant malignancies: an article from the Cancer-Kidney International Network
Clinical Kidney Journal, 2018, vol. 11, no. 3, 315 329 doi: 10.1093/ckj/sfx122 Advance Access Publication Date: 27 October 2017 CKJ Review CKJ REVIEW Risk factors associated with post kidney transplant
More informationSCG: For Transplant patients AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
SCG: For Transplant patients The following guidelines are designed to provide information relating to tacrolimus and to outline the responsibilities of the primary and secondary care teams in the prescribing
More information